Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.
about
Hairy cell leukemia: a diagnosis by endoscopic ultrasound guided fine needle aspirationLong-term follow-up after purine analogue therapy in hairy cell leukaemiaCurrent and emerging treatment options for hairy cell leukemiaHairy cell leukemia: current conceptsBRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.Haematological profile of 21 patients with hairy cell leukaemia in a tertiary care centre of north India.How I treat hairy cell leukemia.Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.Update on the biology and treatment options for hairy cell leukemia.Hairy cell leukemia: A decade long experience of North Indian Hematology Center.Hairy Cell Leukaemia in Oman: Four cases.VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.Clinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential.Mechanisms of apoptosis induction by nucleoside analogs.Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutationPhase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.Efficacy and Safety of Cladribine: Subcutaneous versus Intravenous Administration in Hairy Cell Leukemia Patients.Impact of telomere length on survival in classic and variant hairy cell leukemia.Immunoconjugates in the management of hairy cell leukemia.My treatment approach to hairy cell leukemia.Pentostatin and purine analogs for indolent lymphoid malignancies.2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up.Multiply relapsing hairy cell leukemia responsive to repeated courses of rituximab: a case report.Cladribine Analogues via O⁶-(Benzotriazolyl) Derivatives of Guanine NucleosidesHairy cell leukemia - immunotargets and therapiesCladribine in indolent non-Hodgkin's lymphoma.Cytokines in cancer immunotherapy.Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases.Historical aspects and milestones in the development of effective treatment for hairy cell leukemia.Cladribine in the treatment of hairy cell leukemia: initial and subsequent results.Long-term follow-up studies in hairy cell leukemia.Approach to the patient after relapse of hairy cell leukemia.Hairy cell leukemia: short review, today's recommendations and outlook.Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.Risk of additional cancers in untreated and treated hairy cell leukemia patients.Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis.Chemo-immunotherapy for hairy cell leukemia.Implications of minimal residual disease in hairy cell leukemia after cladribine using immunohistochemistry and immunophenotyping.
P2860
Q25256931-014DAC58-B2E8-467C-BB33-1428B428A311Q26776327-488615D1-3402-41C4-B81B-08DFCAF6516FQ26796423-FE84966A-F4AA-4CA7-BFA5-CE282F51F0A7Q28294251-38493EDA-29ED-45D1-927B-186C2AB7C7F9Q30458424-0AF0277D-ED19-42BC-A4A9-EF5AAEED4128Q33427893-54F2F116-595C-4C5E-849C-B8737DBC5ED3Q33579506-B12C2415-7DA7-4736-8445-2FFA3823CAAAQ33844299-E1C65FE4-18F4-4862-A82D-6D6E5BEF4D3AQ34343369-584D6B92-F14D-49A6-9D88-95BDE3544501Q34686243-83E5FF76-7F09-49A2-8F2D-6A91C5F5ED17Q34783148-D22F5E46-6EF0-4B48-977F-C09FCEF7934BQ35002178-B550B645-23FF-42B5-BE25-1A9050398CB5Q35021459-BA958750-7B00-45CD-9D6D-C697E8DE39FDQ35603389-3080D207-1458-40BB-85E6-0F59A985C343Q35876956-8EB861AC-50C9-4318-9C7F-8C8C7238CC61Q36058502-A2677D70-F1FC-4609-885E-DAF544BF0C9DQ36208306-33CCDFB1-4B8B-4669-986F-0198EAD4B7B8Q36322450-AE9AB83B-BCFC-4991-BB7B-E292AFC38286Q36328016-6E8FAEAB-65CA-4FC4-B66E-54151F90050CQ36399120-0B63A6AC-7061-4D53-9D3D-5C2AF974D699Q36430721-104CB0F5-5453-4D90-A94E-112183E23B7DQ36654614-11A998FE-AD2C-4D18-B140-AC5C2FB1778AQ36687989-E3D07068-A2F6-4D95-85E5-4B746FD3C103Q36827608-BD087530-2173-4AB0-B4EE-8F0753C56A2AQ37031666-3A89D1B5-3188-4FF5-A6B5-F9ADB73362E7Q37134422-953FA24D-946D-44F2-9F01-E80C89A2E3ADQ37148152-E00BECA0-1F6E-495B-9346-7608B5796742Q37242280-F581828D-47F0-4925-ACE5-2D19056DB4D5Q37271941-CD633950-3A7B-4F51-A770-4506E220D58BQ37424784-3293CE60-D26F-4ED5-AFD0-23571D5CB922Q37611065-AAB755E2-35FB-48D8-94AD-8531611FE031Q37611070-4BF41BA5-4478-4F96-8705-717D78159060Q37611075-E83CDCD1-D552-4AD2-88FE-A834ACB7268DQ37611080-D9A658CF-7D60-4DC8-8A3C-EF3EE5F53E22Q37621357-51B39709-4EF6-44D3-9369-AE8EB01843FCQ37623386-0AFE6122-96E4-436A-9DE4-154CF3CF413DQ37650302-216D7130-938B-43D1-9798-056601AF543BQ37816419-AF1A1265-D5EC-4CB5-A41E-5D9EBA3C851AQ37854692-340333CA-CB2A-41BA-9D70-B9C801176666Q37861184-C788D242-5429-4997-A7F7-C77CA298B751
P2860
Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.
@en
Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.
@nl
type
label
Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.
@en
Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.
@nl
prefLabel
Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.
@en
Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.
@nl
P2093
P356
P1476
Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.
@en
P2093
Alan Saven
Carol Burian
Grant R Goodman
James A Koziol
P304
P356
10.1200/JCO.2003.05.093
P407
P577
2003-03-01T00:00:00Z